Home › Research › Risk factors
P1‐243: BIOMARKER‐GUIDED STRATIFICATION APPROACH OF THE CLINICAL CONTINUUM OF ALZHEIMER'S DISEASE USING UNSUPERVISED CLUSTERING METHODS
Nicola Toschi, Simone Lista, Filippo Baldacci, Enrica Cavedo, Henrik Zetterberg, Kaj Blennow, Ingo Kilimann, Stefan Johannes Teipel et al.. Alzheimer s & Dementia, 2019-07-01
Topic: Amyloid, tau and blood-test diagnosis
We found 5 distinct clusters of subjects (N=38, N=16, N=24, N=14, N=21) with a composition statistically independent from that obtained using available clinical diagnostic criteria (each cluster included all phenotypical groups). Two clusters showed biomarker profiles linked to neurodegenerative processes not specifically associated with classical AD-related pathophysiological mechanisms. One cluster showed an increased neuroinflammation biomarker, suggesting that these individuals may benefit from clinical trials targeted to treat neuroinflammation.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Toschi, N., Lista, S., Baldacci, F., Cavedo, E., Zetterberg, H., Blennow, K., et al. (2019). P1‐243: BIOMARKER‐GUIDED STRATIFICATION APPROACH OF THE CLINICAL CONTINUUM OF ALZHEIMER'S DISEASE USING UNSUPERVISED CLUSTERING METHODS. Alzheimer s & Dementia. https://doi.org/10.1016/j.jalz.2019.06.798
Vancouver
Toschi N, Lista S, Baldacci F, Cavedo E, Zetterberg H, Blennow K, et al. P1‐243: BIOMARKER‐GUIDED STRATIFICATION APPROACH OF THE CLINICAL CONTINUUM OF ALZHEIMER'S DISEASE USING UNSUPERVISED CLUSTERING METHODS. Alzheimer s & Dementia. 2019. doi:10.1016/j.jalz.2019.06.798.
BibTeX
@article{toschi2019-f3bd9fcb,
author = {Toschi, Nicola and Lista, Simone and Baldacci, Filippo and Cavedo, Enrica and Zetterberg, Henrik and Blennow, Kaj and Kilimann, Ingo and Teipel, Stefan Johannes and others},
title = {{P1‐243: BIOMARKER‐GUIDED STRATIFICATION APPROACH OF THE CLINICAL CONTINUUM OF ALZHEIMER'S DISEASE USING UNSUPERVISED CLUSTERING METHODS}},
journal = {Alzheimer s \& Dementia},
year = {2019},
doi = {10.1016/j.jalz.2019.06.798},
url = {https://doi.org/10.1016/j.jalz.2019.06.798}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- We found 5 distinct clusters of subjects (N=38, N=16, N=24, N=14, N=21) with a composition statistically independent from that obtained using available clinical diagnostic criteria (each cluster included all phenotypical groups).
- Two clusters showed biomarker profiles linked to neurodegenerative processes not specifically associated with classical AD-related pathophysiological mechanisms.
- One cluster showed an increased neuroinflammation biomarker, suggesting that these individuals may benefit from clinical trials targeted to treat neuroinflammation.
Why it matters
Using clustering, this study found five groups of people across the Alzheimer's clinical continuum whose biomarker profiles did not match standard clinical diagnostic categories. One group had an increased neuroinflammation biomarker, suggesting those individuals might be candidates for trials targeting neuroinflammation.
New to this subject? Start with our plain-English guide: Risk factors, ranked →
Study details
- Participants20
- Evidence strengthModerate
How this study scored 41/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2019 — within 10 year(s) of the newest study here |
| Sample size | 1 / 4 | 20 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 9 year(s) since 2019 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Harald Juergen Hampel: h-index 136 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 23 institution(s) in 6 countries |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 2 / 2 | Free to read |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Risk factors
Also in Risk factors
356 studies in the library are filed under Risk factors with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Risk factors hub.